Glaukos (GKOS) Net Income towards Common Stockholders (2014 - 2026)
Glaukos (GKOS) reported Net Income towards Common Stockholders of -$19.8 million for Q1 2026, down 9.18% year-over-year from -$21.8 million in Q1 2025, and down 130.92% on a QoQ basis from $64.0 million in Q4 2025.
Glaukos (GKOS) has 13 years of Net Income towards Common Stockholders data on file, last reported at -$19.8 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 9.18% year-over-year to -$19.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.3 million (down 65.34% YoY) and the FY2025 annual result came in at $9.9 million, up 702.02% from the prior year.
- Net Income towards Common Stockholders eased to -$19.8 million in Q1 2026 per GKOS's latest filing, from $64.0 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $114.0 million in Q4 2024 and bottomed at -$50.5 million in Q2 2024.
- The 5-year median for Net Income towards Common Stockholders is -$19.8 million (2026), against an average of -$170823.5.
- The widest annual swing landed in 2022, when Net Income towards Common Stockholders soared 391.37%; it then slumped 740.87% in 2023.
- Tracing GKOS's Net Income towards Common Stockholders over 5 years: stood at $69.9 million in 2022, then surged by 45.02% to $101.3 million in 2023, then climbed by 12.58% to $114.0 million in 2024, then sank by 43.9% to $64.0 million in 2025, then tumbled by 130.92% to -$19.8 million in 2026.
- Per Business Quant, the three latest GKOS Net Income towards Common Stockholders figures stand at -$19.8 million (Q1 2026), $64.0 million (Q4 2025), and -$16.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 1.15 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 187,319.30 |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 199.50 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Glaukos | 6.00 Bn | 5.90 Bn | 117.23 Mn | -19.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.78 Mn |
| Dec 31, 2025 | 63.98 Mn |
| Sep 30, 2025 | -16.23 Mn |
| Jun 30, 2025 | -19.66 Mn |
| Mar 31, 2025 | -18.12 Mn |
| Dec 31, 2024 | 114.05 Mn |
| Sep 30, 2024 | -21.41 Mn |
| Jun 30, 2024 | -50.55 Mn |
| Mar 31, 2024 | -40.84 Mn |
| Dec 31, 2023 | 101.31 Mn |
| Sep 30, 2023 | -30.44 Mn |
| Jun 30, 2023 | -32.78 Mn |
| Mar 31, 2023 | -34.63 Mn |
| Dec 31, 2022 | 69.86 Mn |
| Sep 30, 2022 | -27.53 Mn |
| Jun 30, 2022 | -45.54 Mn |
| Mar 31, 2022 | 5.40 Mn |
| Dec 31, 2021 | -23.98 Mn |
| Sep 30, 2021 | 6.23 Mn |
| Jun 30, 2021 | -17.48 Mn |
| Mar 31, 2021 | -16.47 Mn |
| Dec 31, 2020 | -10.65 Mn |
| Sep 30, 2020 | -15.75 Mn |
| Jun 30, 2020 | -39.89 Mn |
| Mar 31, 2020 | -54.06 Mn |
| Dec 31, 2019 | 36.28 Mn |
| Sep 30, 2019 | -13.51 Mn |
| Jun 30, 2019 | -6.31 Mn |
| Mar 31, 2019 | -1.34 Mn |
| Dec 31, 2018 | 1.78 Mn |
| Sep 30, 2018 | -6.62 Mn |
| Jun 30, 2018 | -5.40 Mn |
| Mar 31, 2018 | -2.71 Mn |
| Dec 31, 2017 | 1.01 Mn |
| Sep 30, 2017 | 1.33 Mn |
| Jun 30, 2017 | -3.30 Mn |
| Mar 31, 2017 | 878,000.00 |
| Dec 31, 2016 | 7.78 Mn |
| Sep 30, 2016 | 1.16 Mn |
| Jun 30, 2016 | 2.33 Mn |
| Mar 31, 2016 | 897,000.00 |
| Dec 31, 2015 | 34.49 Mn |
| Sep 30, 2015 | -2.09 Mn |
| Jun 30, 2015 | -32.51 Mn |
| Mar 31, 2015 | -1.46 Mn |
| Dec 31, 2014 | -4.34 Mn |
| Sep 30, 2014 | -1.49 Mn |
| Jun 30, 2014 | -2.49 Mn |
| Mar 31, 2014 | -4.03 Mn |